Drug Profile
Tegaserod - Novartis
Alternative Names: HTF 919; SDZ HTF 919; Zelmac; ZelnormLatest Information Update: 04 Jul 2022
Price :
$50
*
At a glance
- Originator Novartis
- Developer Alfasigma; Novartis
- Class Gastrokinetics; Indoles; Irritable bowel syndrome therapies
- Mechanism of Action Serotonin 4 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Constipation; Irritable bowel syndrome
- Discontinued Dyspepsia; Gastro-oesophageal reflux